Zydus Cadila has approached India’s top drug regulator for restricted emergency approval of ZyCov-D, its three-dose Covid-19 vaccine. If granted, this would be the first DNA vaccine available in the world.
The company, which has also been evaluating the possibility of using a two-dose regimen of ZyCov-D, said that the immunogenicity results “had been found to be equivalent to the current three-dose regimen” — two doses of the vaccine were able to prompt an immune response that was just as good as the response in a three-dose regimen
